Wei Shi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Wei Shi has a total of 2 co-authors. Here are the top co-authors by number of shared publications:
Chengliang Li
Department of General Practice The First Affiliated Hospital of Xi'an Medical University Xi'an China
1 shared publicationMinjuan Wang
Department of Neurosurgery The Second Affiliated Hospital of Xi'an Jiaotong University Xi'an China
1 shared publication
Latest Publications
- 24 March 2021
- Published by Wiley in BioFactors
- Vol. 47 (4) , 600-611
FAM84B acts as a tumor promoter in human glioma via affecting the Akt/GSK‐3β/β‐catenin pathway
Family with sequence similarity 84, member B (FAM84B) has recently emerged as an oncoprotein in multiple types of cancer. However, whether FAM84B modulates the progression of glioma has not been determined. The goals of this work were to assess the possible relationship between FAM84B and glioma. Our data revealed high FAM84B level in glioma specimens and exhibited that the overexpression of FAM84B was correlated with a low survival rate in glioma patients. Cellular functional assays showed that silencing of FAM84B prohibited the proliferation and invasion, and induced the apoptosis of glioma cells. Further results determined that the knockdown of FAM84B remarkably decreased the levels of phosphorylated Akt and glycogen synthase kinase (GSK)‐3β, and active β‐catenin. Inhibition of Akt abolished the FAM84B‐mediated promotion effects on Wnt/β‐catenin pathway. The subcutaneous xenograft assay confirmed that the silencing of FAM84B significantly prohibited the tumorigenicity of glioma cells in vivo. Collectively, the findings from this work demonstrate that the downregulation of FAM84B exhibits a cancer‐suppressive role in human glioma through the regulation of Akt/GSK‐3β/β‐catenin pathway.
- 24 March 2021
- Published by Wiley in BioFactors
- Vol. 47 (4) , 600-611
FAM84B acts as a tumor promoter in human glioma via affecting the Akt/GSK‐3β/β‐catenin pathway
Family with sequence similarity 84, member B (FAM84B) has recently emerged as an oncoprotein in multiple types of cancer. However, whether FAM84B modulates the progression of glioma has not been determined. The goals of this work were to assess the possible relationship between FAM84B and glioma. Our data revealed high FAM84B level in glioma specimens and exhibited that the overexpression of FAM84B was correlated with a low survival rate in glioma patients. Cellular functional assays showed that silencing of FAM84B prohibited the proliferation and invasion, and induced the apoptosis of glioma cells. Further results determined that the knockdown of FAM84B remarkably decreased the levels of phosphorylated Akt and glycogen synthase kinase (GSK)‐3β, and active β‐catenin. Inhibition of Akt abolished the FAM84B‐mediated promotion effects on Wnt/β‐catenin pathway. The subcutaneous xenograft assay confirmed that the silencing of FAM84B significantly prohibited the tumorigenicity of glioma cells in vivo. Collectively, the findings from this work demonstrate that the downregulation of FAM84B exhibits a cancer‐suppressive role in human glioma through the regulation of Akt/GSK‐3β/β‐catenin pathway.